HC Wainwright Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $50.00 target price on the biopharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 145.82% from the stock's current price.

CLDX has been the subject of a number of other research reports. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective for the company. UBS Group reduced their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Morgan Stanley lowered their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Celldex Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $50.90.

Celldex Therapeutics Price Performance

Shares of CLDX traded down $0.92 during midday trading on Friday, hitting $20.34. The stock had a trading volume of 1,473,517 shares, compared to its average volume of 939,494. The stock's 50 day moving average is $19.43 and its 200 day moving average is $21.71. The firm has a market cap of $1.35 billion, a PE ratio of -7.91 and a beta of 1.33. Celldex Therapeutics has a 1 year low of $14.40 and a 1 year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. As a group, equities research analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after purchasing an additional 680 shares in the last quarter. Invesco Ltd. raised its stake in Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after buying an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 878 shares during the last quarter. Values First Advisors Inc. boosted its holdings in Celldex Therapeutics by 3.2% in the first quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock worth $550,000 after acquiring an additional 924 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Celldex Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after acquiring an additional 1,400 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.